GI & Endoscopy

Madison, Wis.-based Exact Sciences — the makers of Cologuard — anticipates revenue between $34.9 and $25.4 million for the fourth quarter of fiscal year 2016.

Here are the top five most read Becker's ASC Review gastroenterology/endoscopy stories for the week of Jan. 2 to Jan. 6, 2017.

A study in Cancer investigated whether mammography and colonoscopy rates increased among fee-for-service Medicare beneficiaries following ACA implementation.

Paul Warfield, MD, is a gastroenterologist with Albuquerque, N.M.-based ABQ Health Partners.

Japan's Takeda Pharmaceuticals and San Diego's PvP Biologics are developing KumaMax, a novel enzyme that breaks down immune-reactive parts of gluten in the stomach, for patients with Celiac disease.

The American Academy of Pediatrics awarded the 2016 Murray Davidson Award to Steven M. Schwarz, MD.

Blue Cross Blue Shield Association's Center for Clinical Effectiveness positively reviewed Madison, Wis.-based Exact Sciences' Cologuard, a fecal-based colonoscopy alternative.

Here are three gastroenterologists in the news this past week.

J. Calvin Coffey, PhD, of Ireland-based University of Limerick, argues that a structure in the digestive system should be classified as a new organ.

Joseph Binns, MD, is a gastroenterologist at Red Bank (N.J.) Gastroenterology.